In the last trading session, 1.16 million Avidity Biosciences Inc (NASDAQ:RNA) shares changed hands as the company’s beta touched 0.91. With the company’s per share price at $28.46 changed hands at $0.06 or 0.21% during last session, the market valuation stood at $3.43B. RNA’s last price was a discount, traded about -96.77% off its 52-week high of $56.00. The share price had its 52-week low at $21.51, which suggests the last value was 24.42% up since then. When we look at Avidity Biosciences Inc’s average trading volume, we note the 10-day average is 1.14 million shares, with the 3-month average coming to 1.54 million.
Analysts gave the Avidity Biosciences Inc (RNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended RNA as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Instantly RNA was in green as seen at the end of in last trading. With action -4.72%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -29.80%, with the 5-day performance at -4.72% in the red. However, in the 30-day time frame, Avidity Biosciences Inc (NASDAQ:RNA) is -8.13% down. Looking at the short shares, we see there were 16.34 million shares sold at short interest cover period of 11.56 days.
The consensus price target for the stock as assigned by Wall Street analysts is 54.5, meaning bulls need an upside of 47.78% from its current market value. According to analyst projections, RNA’s forecast low is 50 with 59 as the target high. To hit the forecast high, the stock’s price needs a -107.31% plunge from its current level, while the stock would need to soar -75.69% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.37%. The 2025 estimates are for Avidity Biosciences Inc earnings to decrease by -36.11%, but the outlook for the next 5-year period is at -4.03% per year.
RNA Dividends
Avidity Biosciences Inc is expected to release its next quarterly earnings report on 2025-May-08.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.17% of Avidity Biosciences Inc shares while 112.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 118.54%. There are 112.41% institutions holding the Avidity Biosciences Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.1121% of the shares, roughly 16.16 million RNA shares worth $660.1 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 10.2093% or 10.92 million shares worth $445.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were T. Rowe Price New Horizons Fund, Inc. and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund . With 4.43 shares estimated at $126.22 million under it, the former controlled 3.68% of total outstanding shares. On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund held about 3.08% of the shares, roughly 3.71 shares worth around $105.68 million.
